首页 > 最新文献

Dermatological Reviews最新文献

英文 中文
Energy-based devices for melasma and postinflammatory hyperpigmentation 治疗黄褐斑和炎症后色素沉着的能量型设备
Pub Date : 2023-02-08 DOI: 10.1002/der2.177
Shane Reynal, Elise Martin, Girish Munavalli

Introduction

Melasma and postinflammatory hyperpigmentation (PIH) are conditions commonly encountered by dermatologists, and they are often distressing to patients. While PIH can improve with time once the inflammatory process is controlled, melasma is a condition that often requires prolonged treatment and maintenance. There are numerous treatment options, ranging from UV protection and topical therapies (such as hydroquinone), to more procedural-based options (chemical peels, micro-needling, and energy-based devices).

Objective

This review will focus on the treatment of melasma and PIH with various energy-based therapies, including laser devices, intense pulsed light (IPL), high-frequency ultrasound, and radiofrequency devices.

Methods

References were collected by using Pubmed with search terms of “laser”, “melasma”, “post-inflammatory hyperpigmentation”, and “energy-based devices.”

Findings

Lasers and IPL target pigment in the epidermis and dermis by using the appropriate wavelengths and principles such as thermal relaxation time and photoacoustic damage. Other lasers, such as pulsed-dye laser (PDL), target the vascular component of melasma. Used alone or in combination with topical treatments, these devices provide improvement in melasma and PIH. In addition, some authors have studied the use of these devices, such as fractionated lasers, in device-assisted drug delivery of topical therapies.

Conclusion

While there is a benefit to the use of these devices, this change is usually temporary and balanced against the side effects of dyspigmentation and scarring. Therefore, these treatments are best used in combination, with a maintenance program that employs both topical therapies, procedures, and energy-based devices.

黄褐斑和炎症后色素沉着(PIH)是皮肤科医生经常遇到的情况,它们通常让患者感到痛苦。虽然一旦炎症过程得到控制,PIH可以随着时间的推移而改善,但黄褐斑是一种通常需要长期治疗和维持的疾病。有许多治疗选择,从紫外线防护和局部治疗(如对苯二酚),到更基于程序的选择(化学削皮、微针和基于能量的设备)。目的本综述将重点介绍各种基于能量的治疗方法,包括激光设备、强脉冲光(IPL)、高频超声和射频设备,以治疗黄褐斑和妊高征。方法使用Pubmed,检索词为“激光”、“黄褐斑”、“炎症后色素沉着过度”和“基于能量的设备”,收集参考文献。“发现激光和强脉冲光通过使用适当的波长和原理,如热弛豫时间和光声损伤,靶向表皮和真皮中的色素。其他激光,如脉冲染料激光(PDL),靶向黄褐斑的血管成分。单独使用或与局部治疗结合使用,这些设备可以改善黄褐斑和PIH。此外,一些作者研究了这些设备,如分级激光,在局部治疗的设备辅助药物递送中的应用。结论虽然使用这些装置有好处,但这种变化通常是暂时的,并与色素沉着和疤痕的副作用相平衡。因此,这些治疗最好与使用局部疗法、程序和基于能量的设备的维护计划结合使用。
{"title":"Energy-based devices for melasma and postinflammatory hyperpigmentation","authors":"Shane Reynal,&nbsp;Elise Martin,&nbsp;Girish Munavalli","doi":"10.1002/der2.177","DOIUrl":"https://doi.org/10.1002/der2.177","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Melasma and postinflammatory hyperpigmentation (PIH) are conditions commonly encountered by dermatologists, and they are often distressing to patients. While PIH can improve with time once the inflammatory process is controlled, melasma is a condition that often requires prolonged treatment and maintenance. There are numerous treatment options, ranging from UV protection and topical therapies (such as hydroquinone), to more procedural-based options (chemical peels, micro-needling, and energy-based devices).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>This review will focus on the treatment of melasma and PIH with various energy-based therapies, including laser devices, intense pulsed light (IPL), high-frequency ultrasound, and radiofrequency devices.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>References were collected by using Pubmed with search terms of “laser”, “melasma”, “post-inflammatory hyperpigmentation”, and “energy-based devices.”</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Findings</h3>\u0000 \u0000 <p>Lasers and IPL target pigment in the epidermis and dermis by using the appropriate wavelengths and principles such as thermal relaxation time and photoacoustic damage. Other lasers, such as pulsed-dye laser (PDL), target the vascular component of melasma. Used alone or in combination with topical treatments, these devices provide improvement in melasma and PIH. In addition, some authors have studied the use of these devices, such as fractionated lasers, in device-assisted drug delivery of topical therapies.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>While there is a benefit to the use of these devices, this change is usually temporary and balanced against the side effects of dyspigmentation and scarring. Therefore, these treatments are best used in combination, with a maintenance program that employs both topical therapies, procedures, and energy-based devices.</p>\u0000 </section>\u0000 </div>","PeriodicalId":100366,"journal":{"name":"Dermatological Reviews","volume":"4 1","pages":"58-66"},"PeriodicalIF":0.0,"publicationDate":"2023-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/der2.177","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50124844","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Hyperpigmentation and melasma—From A to Z 色素沉着过度与黄褐斑——从A到Z
Pub Date : 2023-02-03 DOI: 10.1002/der2.175
Michael H. Gold
{"title":"Hyperpigmentation and melasma—From A to Z","authors":"Michael H. Gold","doi":"10.1002/der2.175","DOIUrl":"https://doi.org/10.1002/der2.175","url":null,"abstract":"","PeriodicalId":100366,"journal":{"name":"Dermatological Reviews","volume":"4 1","pages":"4"},"PeriodicalIF":0.0,"publicationDate":"2023-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50118910","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Guest editor's introduction: Hyperpigmentation and melasma—from A to Z 客座编辑简介:色素沉着与黄褐斑——从A到Z
Pub Date : 2023-02-03 DOI: 10.1002/der2.176
Karan Lal, David Goldberg
{"title":"Guest editor's introduction: Hyperpigmentation and melasma—from A to Z","authors":"Karan Lal,&nbsp;David Goldberg","doi":"10.1002/der2.176","DOIUrl":"https://doi.org/10.1002/der2.176","url":null,"abstract":"","PeriodicalId":100366,"journal":{"name":"Dermatological Reviews","volume":"4 1","pages":"3"},"PeriodicalIF":0.0,"publicationDate":"2023-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50118923","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Superficial radiation therapy for nonmelanoma skin cancer: A review 浅表放射治疗非黑色素瘤皮肤癌:综述
Pub Date : 2023-01-11 DOI: 10.1002/der2.174
Haowei Han, Anita Gade, Francesca M. Ceci, Alec Lawson, Sloane Auerbach, Mark S. Nestor

Background

The high prevalence of nonmelanoma skin cancer (NMSC) has become a global health-care burden. Various modalities have been established to treat NMSC, with surgery being the mainstay approach. Superficial radiation therapy (SRT) has been in use for over a century to treat various conditions. Recent discussion among the dermatological community has promoted the use of SRT for the treatment of NMSC.

Materials and Methods

A literature search was conducted using electronic databases (Medline, Pubmed, Embase, CINAHL, EBSCO) and textbooks, in addition to the authors' clinical experience with SRT.

Results

Multiple retrospective medical record reviews have deemed SRT to be highly effective and associated with minimal side effects. Moreover, SRT yields superior cosmetic results. Over the past decade, SRT has become a mainstay of dermatologist treatment of NMSC due to the new technological advances of the devices. These advances include improved controllability, precision in delivery, additional safety precautions, and have sparked a resurgence in research and clinical evidence on SRT. Most recent data have revealed that the NMSC cure rate is about 93%–100% with excellent 5-year follow-up data. Image-guided SRT using ultrasound guidance may additionally improve cure rates in the future.

Conclusion

SRT has shown to be an effective option for NMSC. It can also be effectively used in the management of keloids. The limitations across most studies encompass localized patient selection and a predominance of retrospective reviews in the literature. Additional research is warranted to further support SRT's efficacy in clinical practice.

背景非黑色素瘤皮肤癌(NMSC)的高患病率已成为全球卫生保健负担。已经建立了多种治疗NMSC的方法,手术是主要的方法。浅表放射治疗(SRT)已经使用了一个多世纪来治疗各种疾病。最近在皮肤学界的讨论促进了SRT治疗NMSC的使用。材料与方法利用电子数据库(Medline, Pubmed, Embase, CINAHL, EBSCO)和教科书以及作者的SRT临床经验进行文献检索。结果:多次回顾性医疗记录审查认为SRT非常有效,副作用最小。此外,SRT可以产生更好的美容效果。在过去的十年中,由于设备的新技术进步,SRT已成为皮肤科医生治疗NMSC的支柱。这些进展包括改进的可控性、输送的精确性、额外的安全预防措施,并引发了SRT研究和临床证据的复苏。最近的数据显示,NMSC的治愈率约为93%-100%,5年随访数据良好。超声引导下的图像引导SRT在未来可能会进一步提高治愈率。结论SRT是治疗NMSC的有效方法。它也可以有效地用于治疗瘢痕疙瘩。大多数研究的局限性包括局部患者选择和文献中回顾性综述的优势。需要进一步的研究来进一步支持SRT在临床实践中的有效性。
{"title":"Superficial radiation therapy for nonmelanoma skin cancer: A review","authors":"Haowei Han,&nbsp;Anita Gade,&nbsp;Francesca M. Ceci,&nbsp;Alec Lawson,&nbsp;Sloane Auerbach,&nbsp;Mark S. Nestor","doi":"10.1002/der2.174","DOIUrl":"10.1002/der2.174","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The high prevalence of nonmelanoma skin cancer (NMSC) has become a global health-care burden. Various modalities have been established to treat NMSC, with surgery being the mainstay approach. Superficial radiation therapy (SRT) has been in use for over a century to treat various conditions. Recent discussion among the dermatological community has promoted the use of SRT for the treatment of NMSC.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and Methods</h3>\u0000 \u0000 <p>A literature search was conducted using electronic databases (Medline, Pubmed, Embase, CINAHL, EBSCO) and textbooks, in addition to the authors' clinical experience with SRT.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Multiple retrospective medical record reviews have deemed SRT to be highly effective and associated with minimal side effects. Moreover, SRT yields superior cosmetic results. Over the past decade, SRT has become a mainstay of dermatologist treatment of NMSC due to the new technological advances of the devices. These advances include improved controllability, precision in delivery, additional safety precautions, and have sparked a resurgence in research and clinical evidence on SRT. Most recent data have revealed that the NMSC cure rate is about 93%–100% with excellent 5-year follow-up data. Image-guided SRT using ultrasound guidance may additionally improve cure rates in the future.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>SRT has shown to be an effective option for NMSC. It can also be effectively used in the management of keloids. The limitations across most studies encompass localized patient selection and a predominance of retrospective reviews in the literature. Additional research is warranted to further support SRT's efficacy in clinical practice.</p>\u0000 </section>\u0000 </div>","PeriodicalId":100366,"journal":{"name":"Dermatological Reviews","volume":"3 6","pages":"409-417"},"PeriodicalIF":0.0,"publicationDate":"2023-01-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/der2.174","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78875744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Guest editor's introduction: Actinic keratoses and skin cancer update 客座编辑介绍:光化性角化病和皮肤癌的最新进展
Pub Date : 2022-12-29 DOI: 10.1002/der2.173
George Martin
albinism and the immunosuppressed, particularly those with HIV. Melanoma remains one of the most lethal skin cancers seen by healthcare providers from all disciplines in medicine. In their article Cutaneous Melanoma: An Update on Pathogenesis, Prevention, and Treatment the authors provide a broad overview of melanoma pathogenesis, diagnosis, surgical intervention and treatment of advanced melanoma. Early detection is key to melanoma survival. Artificial intelligence, still in development for melanoma detection, is discussed as it offers promise as a valid tool for early and accurate detection. The authors focus on the latest in melanoma imaging, the status of wide local excision and sentinel lymph node biopsy in melanoma management, genetic testing, immune and targeted therapy which are all critical in melanoma management. These topics are discussed in the context of the latest data and most current recommendations. Finally, the rapidly evolving treatment regimens for advanced melanoma, which have turned a once hopelessly fatal disease into a chronic disease, are discussed. In Update on immune checkpoint therapy for melanoma the authors summarize the latest updates in each of the major areas of immune checkpoint therapy for metastatic melanoma. In addition to highlighting the pivotal clinical trials that have led to the approval of these therapies in metastatic melanoma they also discuss therapy ‐ related adverse events. They examine the importance of developing predictive biomarkers and their role in melanoma management. Last, the authors identify the future directions necessary to advance the field of immunotherapy in advanced melanoma.
{"title":"Guest editor's introduction: Actinic keratoses and skin cancer update","authors":"George Martin","doi":"10.1002/der2.173","DOIUrl":"10.1002/der2.173","url":null,"abstract":"albinism and the immunosuppressed, particularly those with HIV. Melanoma remains one of the most lethal skin cancers seen by healthcare providers from all disciplines in medicine. In their article Cutaneous Melanoma: An Update on Pathogenesis, Prevention, and Treatment the authors provide a broad overview of melanoma pathogenesis, diagnosis, surgical intervention and treatment of advanced melanoma. Early detection is key to melanoma survival. Artificial intelligence, still in development for melanoma detection, is discussed as it offers promise as a valid tool for early and accurate detection. The authors focus on the latest in melanoma imaging, the status of wide local excision and sentinel lymph node biopsy in melanoma management, genetic testing, immune and targeted therapy which are all critical in melanoma management. These topics are discussed in the context of the latest data and most current recommendations. Finally, the rapidly evolving treatment regimens for advanced melanoma, which have turned a once hopelessly fatal disease into a chronic disease, are discussed. In Update on immune checkpoint therapy for melanoma the authors summarize the latest updates in each of the major areas of immune checkpoint therapy for metastatic melanoma. In addition to highlighting the pivotal clinical trials that have led to the approval of these therapies in metastatic melanoma they also discuss therapy ‐ related adverse events. They examine the importance of developing predictive biomarkers and their role in melanoma management. Last, the authors identify the future directions necessary to advance the field of immunotherapy in advanced melanoma.","PeriodicalId":100366,"journal":{"name":"Dermatological Reviews","volume":"3 6","pages":"353"},"PeriodicalIF":0.0,"publicationDate":"2022-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84677209","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Actinic keratoses and skin cancer update 光化性角化病和皮肤癌的最新进展
Pub Date : 2022-12-21 DOI: 10.1002/der2.172
Michael H. Gold
{"title":"Actinic keratoses and skin cancer update","authors":"Michael H. Gold","doi":"10.1002/der2.172","DOIUrl":"10.1002/der2.172","url":null,"abstract":"","PeriodicalId":100366,"journal":{"name":"Dermatological Reviews","volume":"3 6","pages":"354"},"PeriodicalIF":0.0,"publicationDate":"2022-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76867416","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ethnobotanical notes and pharmacological overview of traditional plant: Adhatoda vasica 传统植物Adhatoda vasica的民族植物学注释和药理学概述
Pub Date : 2022-12-20 DOI: 10.1002/der2.170
Avadh Biharee, Sudha Bhartiya, Dheeraj Dubey, Raju P. Yadav, Arun Sharma, Sachchidanand Pathak, Anu Chaudhary, Arpita Yadav

Background

Adhatoda vasica (Nees.) of the Acanthaceae family has excellent medicinal properties. It is a crucial ingredient in a number of formulations that have been used for decades in India to treat a wide range of health-related difficulties, including fever, jaundice, headaches, colds, cough, whooping cough, asthma, dyspnea, phthisis, chronic bronchitis, and diarrhea. In our country (India) and other countries, the A. vasica plant has great medicinal importance. In the Ayurveda system of treatment, this plant is frequently employed.

Aim

The aim of this comprehensive study is to provide updated information on the phytochemical and pharmacological activity of A. vasica.

Objectives

The stated objectives are to collect systematic data on the botanical description, phytochemistry, pharmacology, and toxicity of A. vasica, as well as detailed information on the many formulations that have conventionally been available on the Indian market.

Method

The relevant information was obtained from a variety of peer-reviewed journals. Google Scholar, PubMed, ScienceDirect, and SciFinder were used to retrieve the journals.

Result

A. vasica is a rich source of therapeutic agents that may have the potential to treat a variety of illnesses, while a detailed investigation of pharmacological activity is needed to confirm the contributing mechanism.

Conclusion

A. vasica is an important medicinal shrub, abundantly found across India, and a rich source of several alkaloids, terpenoids, carbohydrates, and terpenoids that may be used therapeutically in the medical system for treating a range of illnesses. It is a key ingredient in several Ayurvedic and Unani preparations available on the Indian market that are being used to treat a variety of illnesses.

背景:无患子科的阿茶藤具有优良的药用价值。它是印度数十年来使用的多种配方中的关键成分,用于治疗各种与健康相关的困难,包括发烧、黄疸、头痛、感冒、咳嗽、百日咳、哮喘、呼吸困难、肺结核、慢性支气管炎和腹泻。在我国(印度)和其他国家,瓦西卡植物具有重要的药用价值。在阿育吠陀的治疗系统中,这种植物经常被使用。目的本综合研究的目的是提供最新的信息,植物化学和药理活性的输精管。目的所述目标是收集关于A.vasica的植物学描述、植物化学、药理学和毒性的系统数据,以及关于印度市场上传统可用的许多配方的详细信息。方法从各种同行评审期刊中获取相关信息。谷歌学者、PubMed、ScienceDirect和SciFinder被用来检索这些期刊。结果A.vasica是一种丰富的治疗剂来源,可能具有治疗多种疾病的潜力,同时需要对药理活性进行详细研究以证实其作用机制。结论A.vasica是一种重要的药用灌木,在印度各地大量发现,是几种生物碱、萜类化合物、碳水化合物和萜类化合物的丰富来源,可在医疗系统中用于治疗一系列疾病。它是印度市场上几种阿育吠陀和乌纳尼制剂的关键成分,这些制剂被用于治疗各种疾病。
{"title":"Ethnobotanical notes and pharmacological overview of traditional plant: Adhatoda vasica","authors":"Avadh Biharee,&nbsp;Sudha Bhartiya,&nbsp;Dheeraj Dubey,&nbsp;Raju P. Yadav,&nbsp;Arun Sharma,&nbsp;Sachchidanand Pathak,&nbsp;Anu Chaudhary,&nbsp;Arpita Yadav","doi":"10.1002/der2.170","DOIUrl":"https://doi.org/10.1002/der2.170","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p><i>Adhatoda vasica</i> (Nees.) of the Acanthaceae family has excellent medicinal properties. It is a crucial ingredient in a number of formulations that have been used for decades in India to treat a wide range of health-related difficulties, including fever, jaundice, headaches, colds, cough, whooping cough, asthma, dyspnea, phthisis, chronic bronchitis, and diarrhea. In our country (India) and other countries, the <i>A. vasica</i> plant has great medicinal importance. In the Ayurveda system of treatment, this plant is frequently employed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>The aim of this comprehensive study is to provide updated information on the phytochemical and pharmacological activity of <i>A. vasica</i>.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>The stated objectives are to collect systematic data on the botanical description, phytochemistry, pharmacology, and toxicity of <i>A. vasica</i>, as well as detailed information on the many formulations that have conventionally been available on the Indian market.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Method</h3>\u0000 \u0000 <p>The relevant information was obtained from a variety of peer-reviewed journals. Google Scholar, PubMed, ScienceDirect, and SciFinder were used to retrieve the journals.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Result</h3>\u0000 \u0000 <p><i>A. vasica</i> is a rich source of therapeutic agents that may have the potential to treat a variety of illnesses, while a detailed investigation of pharmacological activity is needed to confirm the contributing mechanism.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p><i>A. vasica</i> is an important medicinal shrub, abundantly found across India, and a rich source of several alkaloids, terpenoids, carbohydrates, and terpenoids that may be used therapeutically in the medical system for treating a range of illnesses. It is a key ingredient in several Ayurvedic and Unani preparations available on the Indian market that are being used to treat a variety of illnesses.</p>\u0000 </section>\u0000 </div>","PeriodicalId":100366,"journal":{"name":"Dermatological Reviews","volume":"4 5","pages":"211-222"},"PeriodicalIF":0.0,"publicationDate":"2022-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68179907","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Chemical peels for the management of melasma and hyperpigmentation 治疗黄褐斑和色素沉着过度的化学果皮
Pub Date : 2022-12-16 DOI: 10.1002/der2.169
Maria Karim, Darlene Diep, Omobola Onikoyi, Shereen Teymour, Karan Lal

Melasma is often a difficult disease to treat, and can be psychologically distressing to patients. Currently, the gold standard for the treatment of melasma is hydroquinone. While this treatment has been used for many years, it does not come without risks with overuse. Chemical peels have also become an option for the treatment of melasma, but their efficacy and safety in comparison to hydroquinone has not yet been established. This review aims to investigate the various types, efficacy, and safety of chemical peels used to treat melasma.

黄褐斑通常是一种难以治疗的疾病,对患者来说可能会带来心理上的痛苦。目前,治疗黄褐斑的金标准是对苯二酚。虽然这种治疗方法已经使用了很多年,但它并非没有过度使用的风险。化学果皮也已成为治疗黄褐斑的一种选择,但与对苯二酚相比,其疗效和安全性尚未确定。本综述旨在研究用于治疗黄褐斑的化学果皮的各种类型、疗效和安全性。
{"title":"Chemical peels for the management of melasma and hyperpigmentation","authors":"Maria Karim,&nbsp;Darlene Diep,&nbsp;Omobola Onikoyi,&nbsp;Shereen Teymour,&nbsp;Karan Lal","doi":"10.1002/der2.169","DOIUrl":"https://doi.org/10.1002/der2.169","url":null,"abstract":"<p>Melasma is often a difficult disease to treat, and can be psychologically distressing to patients. Currently, the gold standard for the treatment of melasma is hydroquinone. While this treatment has been used for many years, it does not come without risks with overuse. Chemical peels have also become an option for the treatment of melasma, but their efficacy and safety in comparison to hydroquinone has not yet been established. This review aims to investigate the various types, efficacy, and safety of chemical peels used to treat melasma.</p>","PeriodicalId":100366,"journal":{"name":"Dermatological Reviews","volume":"4 1","pages":"53-57"},"PeriodicalIF":0.0,"publicationDate":"2022-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50134378","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Guest editors' introduction—Vitiligo and hypopigmentation 客座编辑介绍-白癜风和色素减退
Pub Date : 2022-12-13 DOI: 10.1002/der2.171
Somesh Gupta, Venkatram Mysore
Editorial We are living in an exciting era of vitiligo research. There has been an unprecedented focus on vitiligo in the field of dermatology, pharmaceutical and publishing industry, as well as among academic institutions. Partly, this is due to economic growth in countries with people of skin of color where vitiligo has a significant impact on quality of life, and therefore, a rise in the demand for treatment of vitiligo as the purchasing power of patients improves. Still, in most countries, the treatment of vitiligo as a disease is not covered in the health insurance and the treatment of vitiligo becomes burdensome for the patients. Till recently, the only topical cream approved by US ‐ FDA for treatment of vitiligo, was monobenzyl ether of hydroquinone, a depigmenting cream which is used for bleaching of residual pigment when repigmentation is not a realistic goal due to widespread body surface area involvement in vitiligo. However, in a first, US ‐ FDA has recently approved, in the year 2022, Ruxolitinib as a repigmenting topical agent for treatment of vitiligo. This is a sign of paradigm shift in the approach, where vitiligo is not merely considered a cosmetic nuisance but, more realistically, an autoimmune disease with significant psychosocial problems. The current issue of Dermatological reviews is a welcome addition in the existing literature on vitiligo. Many renowned researchers from across the world have contributed to this issue. The issue comprehensively covers the basic science, psychological aspects, clinical science, clinical signs and biomarkers of disease activity and disease stability, recent advances in the medical treatment, and surgical approaches of treatment for vitiligo. Rarely, we do get such an extensive discussion on vitiligo in any dermatology journals. Therefore, this issue will be a valuable resource on recent advances in the science related to vitiligo. We hope you will enjoy reading these papers.
{"title":"Guest editors' introduction—Vitiligo and hypopigmentation","authors":"Somesh Gupta,&nbsp;Venkatram Mysore","doi":"10.1002/der2.171","DOIUrl":"10.1002/der2.171","url":null,"abstract":"Editorial We are living in an exciting era of vitiligo research. There has been an unprecedented focus on vitiligo in the field of dermatology, pharmaceutical and publishing industry, as well as among academic institutions. Partly, this is due to economic growth in countries with people of skin of color where vitiligo has a significant impact on quality of life, and therefore, a rise in the demand for treatment of vitiligo as the purchasing power of patients improves. Still, in most countries, the treatment of vitiligo as a disease is not covered in the health insurance and the treatment of vitiligo becomes burdensome for the patients. Till recently, the only topical cream approved by US ‐ FDA for treatment of vitiligo, was monobenzyl ether of hydroquinone, a depigmenting cream which is used for bleaching of residual pigment when repigmentation is not a realistic goal due to widespread body surface area involvement in vitiligo. However, in a first, US ‐ FDA has recently approved, in the year 2022, Ruxolitinib as a repigmenting topical agent for treatment of vitiligo. This is a sign of paradigm shift in the approach, where vitiligo is not merely considered a cosmetic nuisance but, more realistically, an autoimmune disease with significant psychosocial problems. The current issue of Dermatological reviews is a welcome addition in the existing literature on vitiligo. Many renowned researchers from across the world have contributed to this issue. The issue comprehensively covers the basic science, psychological aspects, clinical science, clinical signs and biomarkers of disease activity and disease stability, recent advances in the medical treatment, and surgical approaches of treatment for vitiligo. Rarely, we do get such an extensive discussion on vitiligo in any dermatology journals. Therefore, this issue will be a valuable resource on recent advances in the science related to vitiligo. We hope you will enjoy reading these papers.","PeriodicalId":100366,"journal":{"name":"Dermatological Reviews","volume":"3 5","pages":"259"},"PeriodicalIF":0.0,"publicationDate":"2022-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84420662","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Biomarkers and clinical indicators of disease activity in vitiligo 白癜风疾病活动性的生物标志物和临床指标
Pub Date : 2022-12-09 DOI: 10.1002/der2.168
Liesbeth Delbaere, Reinhart Speeckaert, Sandrine Herbelet, Arno Belpaire, Jolien Duponselle, Nanja van Geel

Background: The management of vitiligo is guided by the assessment of disease activity. However, this assessment is hampered by the absence of a highly feasible and reliable single marker to evaluate activity. Furthermore, the need for an objective, easy, preferably noninvasive marker is further stressed by the increased amount of research performed on new treatment strategies for vitiligo.

Objectives: In this review, the available research on clinical signs linked to disease activity, and biomarkers in tissues and blood are summarized.

Results: In the group of clinical signs, the Koebner phenomenon has the strongest evidence of an association with disease activity, while confetti-like depigmentation is gaining importance and seems to outweigh this role. For the tissue markers, the most evidence is available for histopathological findings, such as epidermal spongiosis with vacuolar degeneration in the basal cells and inflammatory infiltrate. Circulating biomarkers such as interleukin-1β (IL-1β), IL-17, interferon-γ, tumor growth factor-β, soluble cluster of differentiation 25, autoantibodies, and oxidative stress markers show the most promising results. Nevertheless, none of them are currently regarded as the gold standard.

Discussion: In conclusion, we encourage researchers to investigate various biomarkers and clinical signs in their trials in a standardized manner to get insight into their exact value, so they can be used to optimize treatment selection, gain insight into the disease, and predict future disease progression.

背景:白癜风的治疗以疾病活动性评估为指导。然而,由于缺乏高度可行和可靠的单一标志物来评估活性,这种评估受到阻碍。此外,对白癜风新治疗策略的研究越来越多,进一步强调需要一种客观、简单、最好是非侵入性的标志物。目的:本文综述了与疾病活动相关的临床体征以及组织和血液中生物标志物的研究进展。结果:在临床症状组中,Koebner现象与疾病活动相关的证据最强,而五彩纸屑样色素沉着越来越重要,似乎超过了这一作用。对于组织标志物,最有力的证据是组织病理学发现,如表皮海绵状病伴基底细胞空泡变性和炎症浸润。循环生物标志物,如白细胞介素-1β (IL-1β)、IL-17、干扰素-γ、肿瘤生长因子-β、可溶性分化簇25、自身抗体和氧化应激标志物显示出最有希望的结果。然而,目前没有一个被认为是黄金标准。讨论:总之,我们鼓励研究人员在他们的试验中以标准化的方式调查各种生物标志物和临床体征,以了解它们的确切价值,从而可以用于优化治疗选择,深入了解疾病,并预测未来的疾病进展。
{"title":"Biomarkers and clinical indicators of disease activity in vitiligo","authors":"Liesbeth Delbaere,&nbsp;Reinhart Speeckaert,&nbsp;Sandrine Herbelet,&nbsp;Arno Belpaire,&nbsp;Jolien Duponselle,&nbsp;Nanja van Geel","doi":"10.1002/der2.168","DOIUrl":"10.1002/der2.168","url":null,"abstract":"<p><b>Background</b>: The management of vitiligo is guided by the assessment of disease activity. However, this assessment is hampered by the absence of a highly feasible and reliable single marker to evaluate activity. Furthermore, the need for an objective, easy, preferably noninvasive marker is further stressed by the increased amount of research performed on new treatment strategies for vitiligo.</p><p><b>Objectives</b>: In this review, the available research on clinical signs linked to disease activity, and biomarkers in tissues and blood are summarized.</p><p><b>Results</b>: In the group of clinical signs, the Koebner phenomenon has the strongest evidence of an association with disease activity, while confetti-like depigmentation is gaining importance and seems to outweigh this role. For the tissue markers, the most evidence is available for histopathological findings, such as epidermal spongiosis with vacuolar degeneration in the basal cells and inflammatory infiltrate. Circulating biomarkers such as interleukin-1β (IL-1β), IL-17, interferon-γ, tumor growth factor-β, soluble cluster of differentiation 25, autoantibodies, and oxidative stress markers show the most promising results. Nevertheless, none of them are currently regarded as the gold standard.</p><p><b>Discussion</b>: In conclusion, we encourage researchers to investigate various biomarkers and clinical signs in their trials in a standardized manner to get insight into their exact value, so they can be used to optimize treatment selection, gain insight into the disease, and predict future disease progression.</p>","PeriodicalId":100366,"journal":{"name":"Dermatological Reviews","volume":"3 5","pages":"289-307"},"PeriodicalIF":0.0,"publicationDate":"2022-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78336522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Dermatological Reviews
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1